HCC : PE-062 ; The Radiotherapy on HCC in caudate lobe = HCC : PE-062 ; The Radiotherapy on HCC in caudate lobe

다국어 초록 (Multilingual Abstract)

Background: Hepatocelluar carcinoma (HCC) in caudate lobe has poor prognosis and is challenging to treat with surgery, radiofreqeuncy ablation (RFA), transcatheter arterial embolization (TACE) because of its unique anatomic location. This study was designed to assess the efficacy and safety of radiotherapy (RT) for HCC in the caudate lobe. Methods: Between January 1996 and August 2011, 58 patients with HCC in caudate lobe were treated with RT. Fifty cases were treated after the failure of previous RFA or TACE. Eight patients were treated as definitive aim. Most of the patients were treated with RT alone (44%) while the others were treated with RT with intra-arterial (34%) or systemic chemotherapy (15%), RT after TACE (7%) within 1 month. Median radiation dose was 45Gy (range, 30.6 - 80 Gy) in 25 fractions. The tumor response was determined by CT scans at post-RT 3 months. Results: The median follow-up period after RT was 10.6 months (range, 1 ? 93 months). The 1 year- and 2 year-local control rates were 73.5% and 47.7%, respectively, and 1 yearand 2 year-overall survival rates were 53.8% and 40.4%, respectively. Complete response was achieved in two patients. In-field local control was achieved in 70% of patients. During the follow-up, 14 patients (24%) developed intra-hepatic metastases and eight patients (13%) developed extra-hepatic metastases: lung, distant lymph nodes, bone, and brain. Seven patients developed grade 1 nausea or anorexia during RT. There were no grade 3 or greater treatment-related toxicities. Conclusions: Radiotherapy appears to be an effective and feasible treatment modality for HCC in caudate lobe.